Agenus Inc. AGEN · Stock Open Agenus Inc. in new tab
Agenus Inc. Analysis (AGEN)
Is Agenus Inc. a good investment? Agenus Inc. (AGEN) is currently trading at 7.15 USD. Market analysts have a consensus price target of 19.50 USD. This suggests a potential upside from current levels.
In terms of valuation, the stock trades at a P/E ratio of 2.45. This relatively low multiple may signal that Agenus Inc. is undervalued compared to historical market norms.
Earnings Schedule: Agenus Inc. is expected to release its next earnings report on Nov. 9, 2026. The market consensus estimate for Forward EPS is -0.06.
Investor FAQ
Does Agenus Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Agenus Inc.?
Agenus Inc. is classified as a Stock. You can compare it against 5 other assets in the "Related Symbols" list on this page.
When is the next earnings date?
The next earnings date is projected to be Nov. 9, 2026. The company currently has a trailing EPS of 2.99.
Company Profile
Agenus Inc., a clinical-stage biotechnology company, discovers and develops immunotherapies for cancer and infectious diseases in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, a programmed death receptor-1 (PD-1) blocking antibody; AGEN1181, a human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody that is in Phase 2 trials in metastatic colorectal cancer (mCRC), pancreatic cancer, and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFß TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in clinical development; and BMS-986442, a TIGIT bispecific antibodies. In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monoclonal antibodies; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; and AGEN1884. The company operates under the Agenus, MiNK, Prophage, Retrocyte Display, and STIMULON trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., UroGen Pharma Ltd., Gilead Sciences, Inc., Incyte Corporation, and Merck Sharp & Dohme. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.
| Split Date | Split Ratio to 1 |
|---|---|
| Oct. 3, 2011 | 0.170000 |
| April 12, 2024 | 0.050000 |
Community Discussion